Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience.
Wellington Fernandes da SilvaLidiane Inês da RosaFernanda Salles SeguroDouglas Rafaele Almeida SilveiraIsrael BenditValeria BuccheriElvira Deolinda Rodrigues Pereira VellosoVanderson Geraldo RochaEduardo Magalhaes RegoPublished in: Clinics (Sao Paulo, Brazil) (2020)
In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- palliative care
- acute lymphoblastic leukemia
- oxidative stress
- prognostic factors
- peritoneal dialysis
- diffuse large b cell lymphoma
- multiple myeloma
- pain management
- mesenchymal stem cells
- replacement therapy
- hodgkin lymphoma
- patient reported
- smoking cessation
- chemotherapy induced